Skip to main content
SpringerLink
Log in

Certolizumab pegol: a guide to its use in Crohn’s disease

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Blick SKA, Curran MP. Certolizumab pegol in Crohn’s disease. Biodrugs 2007; 21(3): 195–201

    Article  PubMed  CAS  Google Scholar 

  2. Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol 2001 Mar; 96(3): 635–43

    Article  PubMed  CAS  Google Scholar 

  3. Sandborn WJ. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord 2005; 5(1): 10–8

    PubMed  Google Scholar 

  4. Löwenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn’s disease: why, when and how? Drugs 2006; 66(11): 1431–9

    Article  PubMed  Google Scholar 

  5. Countering Crohn’s disease with Cimzia: novel TNF-α blocker close to market. Pharm Diag Innovation 2005; 3 (8): 6–9

  6. Weir N, Athwal D, Brown D, et al. A new generation of high-affinity humanized PEGylated Fab′ fragment anti-tumor necrosis factor-alpha monoclonal antibodies. Therapy 2006; 3(4): 535–45

    CAS  Google Scholar 

  7. Gramlick G, Fossati G, Nesbitt A. Neutralization of soluble and membrane tumor necrosis factor-α (TNF-α) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-α receptor-specific bioassays. Gastroenterology 2006; 130Suppl. 2: A–697

    Google Scholar 

  8. Gramlick G, Fossati G, Henry A, et al. Assessment of the affinity for soluble TNF and the neutralising potency against soluble and membrane TNF of the anti-TNF agents certolizumab pegol, adalimumab, etanercept and infliximab. Ann Rheum Dis 2006; 65 Suppl. II: 456

    Google Scholar 

  9. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26-week, placebo-controlled phase III study (PRECiSE I) [abstract no. 745]. Gastroenterology 2006 Apr; 130(4 Suppl. 2): 107. Plus oral presentation presented at Digestive Disease Week; 2006 May 20–25; Los Angeles (CA)

    Google Scholar 

  10. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007 Jul 19; 357(3): 228–38

    Article  PubMed  CAS  Google Scholar 

  11. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005 Sep; 129(3): 807–18

    Article  PubMed  CAS  Google Scholar 

  12. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007 Jul 19; 357(3): 239–50

    Article  PubMed  CAS  Google Scholar 

  13. Vetterlein OM, Kopotsha T, Nesbitt AM, et al. Antibodies to infliximab in patients with Crohn’s disease do not cross-react with certolizumab pegol [abstract no. MON-G-261]. Gut 2006; 55Suppl. V: A133

    Google Scholar 

  14. Schreiber S, Colombel JF, Panes J, et al. Recent-onset Crohn’s disease shows higher remission rates and durability of response to treatment with subcutaneous monthly certolizumab pegol: results from an analysis of the PRECiSE 2 phase III study [abstract no. MON-G-255]. Gut 2006; 55Suppl. V: A131

    Google Scholar 

  15. Feagan B, Brown M, Gerlier L, et al. The effects of certolizumab pegol on work productivity and daily activities of Crohn’s disease patients: data from PRECiSE 2 [abstract no. MON-G-291]. Gut 2006; 55Suppl. V: A139

    Google Scholar 

  16. Feagan B, Coteur G, Keninger DL, et al. The burden of Crohn’s disease on patients-reported health status was relieved following maintenance treatment with certolizumab pegol 400mg every 4 weeks: data from PRECiSE 2 [abstract no. MON-G-220]. Gut 2006; 55 Suppl. V: A124

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Certolizumab pegol: a guide to its use in Crohn’s disease. Drugs Ther. Perspect 23, 5–8 (2007). https://doi.org/10.2165/00042310-200723110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200723110-00002

Search

Navigation